Screening and identification of an anti-PD-1 nanobody with antitumor activity
Sign Up to like & getrecommendations! Published in 2022 at "Bioscience Reports"
DOI: 10.1042/bsr20221546
Abstract: Abstract Blocking of programmed death protein 1 (PD-1) or its ligand PD-L1 with corresponding antibody to enhance T-cell response and mediate antitumor activity has been successfully applied in clinical practice. Several immune checkpoint inhibitors including… read more here.
Keywords: antitumor; antitumor activity; anti nanobody; identification anti ... See more keywords
T-cell mediated targeted delivery of anti-PD-L1 nanobody overcomes poor antibody penetration and improves PD-L1 blocking at the tumor site.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer immunology research"
DOI: 10.1158/2326-6066.cir-21-0801
Abstract: Monoclonal antibodies blocking immune checkpoints such as PD-L1 have yielded strong clinical benefits in many cancer types. Still, the current limitations are the lack of clinical response in a majority of patients and the development… read more here.
Keywords: tumor site; anti nanobody; tumor; antibody ... See more keywords